表紙
市場調査レポート

再発性多形性膠芽腫 (GBM):世界の治験動向

Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 299732
出版日 ページ情報 英文 903 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
再発性多形性膠芽腫 (GBM):世界の治験動向 Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016
出版日: 2016年08月24日 ページ情報: 英文 903 Pages
概要

当レポートでは、再発性多形性膠芽腫 (GBM) の治療薬に関する治験について調査分析し、治験数および被験者数、段階別・相別の状況、有望企業、開発中の治療薬の情報、治験プロファイルなどを提供しています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:癌治療薬の治験における再発性多形性膠芽腫 (GBM) の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験における再発性多形性膠芽腫 (GBM) の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

再発性多形性膠芽腫 (GBM) 治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3658CTIDB

GlobalData's clinical trial report, "Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2016" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Five Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials 27
  • Prominent Drugs 28
  • Latest Clinical Trials News on Glioblastoma Multiforme (GBM) 29
  • Aug 04, 2016: DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401 29
  • Jul 25, 2016: ImmunoCellular Therapeutics Provides Update on Lead Cancer Immunotherapy ICT-107 29
  • Jul 15, 2016: ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 30
  • Jul 12, 2016: VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 30
  • Jun 28, 2016: New Data Suggests Improved Tumor Response For The Combination of AZIXA and Immune Checkpoint Inhibitors in The Treatment of Cancer 31
  • Jun 07, 2016: ImmunoCellular Therapeutics Treats First Patient in ICT-107 Phase 3 Registrational Trial in Newly Diagnosed Glioblastoma 31
  • Jun 06, 2016: CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting 32
  • Jun 06, 2016: TRACON Pharmaceuticals Announces Positive Results from TRC105 Clinical Trials at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting 33
  • Jun 02, 2016: ImmunoBody vaccine to be developed for the treatment of glioblastoma multiforme 34
  • Clinical Trial Profile Snapshots 35

Appendix 900

  • Abbreviations 900
  • Definitions 900
  • Research Methodology 901
  • Secondary Research 901
  • About GlobalData 902
  • Contact Us 902
  • Disclaimer 902
  • Source 903

List of Tables

List of Tables

  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
  • Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2016* 14
  • Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2016* 17
  • Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase, 2016* 20
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures

List of Figures

  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
  • Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2016* 14
  • Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2016* 17
  • Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
  • GlobalData Methodology 901
Back to Top